- Home
- BMEA vs UCL Comparison
BMEA vs UCL Comparison
Compare BMEA & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- UCL
- Stock Information
- Founded
- BMEA 2017
- UCL 2014
- Country
- BMEA United States
- UCL Hong Kong
- Employees
- BMEA 63
- UCL N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- UCL Telecommunications Equipment
- Sector
- BMEA Health Care
- UCL Consumer Discretionary
- Exchange
- BMEA Nasdaq
- UCL Nasdaq
- Market Cap
- BMEA 96.9M
- UCL 144.5M
- IPO Year
- BMEA 2021
- UCL 2020
- Fundamental
- Price
- BMEA $1.36
- UCL $2.22
- Analyst Decision
- BMEA Strong Buy
- UCL
- Analyst Count
- BMEA 7
- UCL 0
- Target Price
- BMEA $8.86
- UCL N/A
- AVG Volume (30 Days)
- BMEA 1.7M
- UCL 18.0K
- Earning Date
- BMEA 11-04-2025
- UCL 11-12-2025
- Dividend Yield
- BMEA N/A
- UCL N/A
- EPS Growth
- BMEA N/A
- UCL N/A
- EPS
- BMEA N/A
- UCL 0.02
- Revenue
- BMEA N/A
- UCL $89,277,000.00
- Revenue This Year
- BMEA N/A
- UCL N/A
- Revenue Next Year
- BMEA N/A
- UCL $20.86
- P/E Ratio
- BMEA N/A
- UCL $96.16
- Revenue Growth
- BMEA N/A
- UCL 3.72
- 52 Week Low
- BMEA $1.22
- UCL $0.80
- 52 Week High
- BMEA $8.99
- UCL $4.19
- Technical
- Relative Strength Index (RSI)
- BMEA 40.15
- UCL 47.65
- Support Level
- BMEA $1.22
- UCL $2.10
- Resistance Level
- BMEA $1.35
- UCL $2.25
- Average True Range (ATR)
- BMEA 0.10
- UCL 0.12
- MACD
- BMEA 0.00
- UCL 0.02
- Stochastic Oscillator
- BMEA 31.16
- UCL 41.38
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.